Key Highlights
- AI Proteins names Dr. Philip E. Brandish as Chief Development Officer (CDO).
- Dr. Brandish brings extensive experience in drug discovery and development.
- Previously held leadership roles at Bicycle Therapeutics and Merck & Co.
- Will lead AI Proteins’ target selection, prioritization, and development efforts.
- Company’s AI-driven miniprotein platform accelerates lead molecule development.
Source: Business Wire
Notable Quotes
- “Phil is a crucial addition to our leadership team, bringing extensive experience developing drugs, driving collaborations, and leading high-performing teams. Phil joins us at an exciting time, as our platform is churning out lead molecules that address highly-demanding therapeutic criteria at breakneck speed. Phil will lead our rigorous target selection and prioritization process in addition to our development efforts.” — Dr. Chris Bahl, President, CEO, and Founder at AI Proteins
- “I am thrilled and privileged to be joining forces with Chris and the extraordinary team of scientists at AI Proteins. The AI-based miniprotein discovery platform that they have created and reduced to practice presents an unparalleled opportunity. That is, to create impactful new therapeutics that precisely meet the design goals dictated by the disease biology and by what patients need.” — Dr. Philip Brandish, Chief Development Officer at AI Proteins
Why This Matters
AI Proteins is at the forefront of AI-driven protein therapeutics, pioneering the use of artificial intelligence to design de novo miniproteins with enhanced therapeutic potential. The appointment of Dr. Philip Brandish strengthens the company’s leadership team, bringing a seasoned expert with a track record of advancing preclinical and clinical-stage therapeutics. As AI Proteins continues to innovate, this move reinforces its commitment to rapidly developing novel therapeutics that meet precise disease and patient needs.
